Study of the ZyMōt Sperm Selection Method and Its Effect on Embryo Ploidy.

Launched by INSTITUTO VALENCIANO DE INFERTILIDAD, IVI VALENCIA · Apr 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new sperm selection method called ZyMōt, which aims to improve the quality of sperm used in fertility treatments. Traditional methods can sometimes harm sperm DNA, which may affect the chances of successful fertilization and embryo development. The ZyMōt device uses a different approach that doesn’t involve spinning the sperm sample, which could help maintain healthier sperm and potentially increase the chances of pregnancy, especially for couples facing unexplained infertility or other related issues.

To participate in the trial, couples need to be undergoing a specific fertility treatment called ICSI with a genetic test for embryo quality. Men must be over 18 and provide a fresh sperm sample that meets certain criteria, while women must be older than 37 and have a minimum number of mature eggs. Participants will undergo standard procedures and be monitored for the effects of using the ZyMōt device compared to traditional methods. This study is important because it could lead to better fertility outcomes for couples trying to conceive.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Couples undergoing an ICSI cycle with PGT-A (Preimplantational Genetic Test for Aneuploidy).
• • Males over 18 years of age whose semen sample meets the basic conditions predetermined by the ZyMōt Multi 850µL chip.
• • Fresh semen samples.
• • Embryos are to be deposited in a time-lapse incubator.
• • Women over 37 years of age who have obtained in follicular puncture a number of MII oocytes greater than or equal to 4.
• Exclusion Criteria:
• • Males with severe asthenozoospermia (\<10% progressively motile spermatozoa), globozoospermia (spermatozoa with morphological alterations and lack of acrosome) and/or azoospermia (absence of spermatozoa in the ejaculate).
• • Seminal samples obtained by testicular biopsy.
• • Samples incubated with calcium ionophore.
• • Males and females with previously known abnormal karyotype.
• • Oocytes coming from the oocyte donation program.